1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

In Brief

Novartis makes OTC exec change following recall and plant shutdown; Prestige Brands adopts plan to deter Genomma takeover bid; Pfizer scoops up Emergen-C maker Alacer; CSPI threatens Amway with Nutrilite suit; more news In Brief.

Novartis AG names Brian McNamara to replace departing OTC division head Naomi Kelman as the company attempts to recover from a recall and plant shutdown in the consumer health division. McNamara took over Feb. 29 as division head of Novartis OTC, which has a seat on the Swiss firm’s executive committee. He joined Novartis in 2004 after 16 years at Procter & Gamble Co., and has served as Novartis’ OTC region head in both Europe and the Americas. Kelman’s tenure at Novartis lasted just under a year; she left a leadership role at Johnson & Johnson’s diabetes care business for Novartis in March 2011, just as the company was realigning to emphasize the importance of the consumer business Also see "Novartis Makes Room For OTC Division Head On Executive Committee" - Pink Sheet, 21 February, 2011.. McNamara takes the reins of a division attempting to get its Lincoln, Neb., facility back online by mid-year after FDA inspectors found persistent quality control problems and the firm recalled Excedrin and other OTCs Also see "FDA Pressure Likely In Novartis OTC Plant Shutdown, Recalls" - Pink Sheet, 6 February, 2012..

Prestige Brands Holdings Inc.’s board of directors adopts a stockholder rights plan to discourage a hostile takeover bid from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 
• By Bridget Silverman

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

Capricor Gets Complete Response For DMD Cell Therapy: Unconvincing Data Or New Attitude At FDA?

 
• By Joseph Haas

Seven weeks before its action date and a month after an advisory committee was hastily cancelled, Capricor gets a CRL for its cell therapy deramiocel in DMD-related cardiomyopathy citing efficacy and manufacturing concerns. It has a Phase III study nearing readout, though.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By Sue Sutter

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

More from North America

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 
• By Bridget Silverman

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.

US FDA Asking Questions About Commissioner’s Voucher Program With Details Scarce

 
• By Derrick Gingery

FDA staff are trying to plan for program implementation in the absence of critical eligibility and other details, although guidance may be coming soon.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 
• By Sarah Karlin-Smith

US FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.